Title |
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
|
---|---|
Published in |
Cochrane database of systematic reviews, December 2012
|
DOI | 10.1002/14651858.cd006921.pub3 |
Pubmed ID | |
Authors |
Jodie M Burton, Paul W O'Connor, Marika Hohol, Joseph Beyene |
Abstract |
This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006921. DOI: 10.1002/14651858.CD006921.pub2).Multiple sclerosis (MS), a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS), is characterized by recurrent relapses of CNS inflammation ranging from mild to severely disabling. Relapses have long been treated with steroids to reduce inflammation and hasten recovery. However, the commonly used intravenous methylprednisolone (IVMP) requires repeated infusions with the added costs of homecare or hospitalization, and may interfere with daily responsibilities. Oral steroids have been used in place of intravenous steroids, with lower direct and indirect costs. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Panama | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 1% |
United States | 1 | <1% |
Unknown | 191 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 28 | 14% |
Student > Bachelor | 26 | 13% |
Researcher | 22 | 11% |
Other | 17 | 9% |
Student > Ph. D. Student | 17 | 9% |
Other | 22 | 11% |
Unknown | 62 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 62 | 32% |
Nursing and Health Professions | 12 | 6% |
Agricultural and Biological Sciences | 10 | 5% |
Psychology | 9 | 5% |
Neuroscience | 7 | 4% |
Other | 22 | 11% |
Unknown | 72 | 37% |